Recent Company News

• 10:47 PM ET Aug 06, 2026
  

  StreetAccount Summary - Trading higher/lower: Asia mid-morning

• 10:44 PM ET Aug 06, 2026
  

  StreetAccount Summary - Trading higher/lower: Hong Kong mid-morning

• 09:00 AM ET Aug 06, 2026
  

  Transcript Intelligence: ZAI Lab Q2 Earnings Guidance

• 09:00 AM ET Aug 06, 2026
  

  Transcript Intelligence: ZAI Lab Q2 Earnings Themes

• 09:00 AM ET Aug 06, 2026
  

  Transcript Intelligence: ZAI Lab Q2 Earnings Q&A

• 06:44 AM ET Aug 06, 2026
  

  StreetAccount Metrics Recap - ZAI Lab Q2 Earnings ($18.37, 0.00)

• 06:37 AM ET Aug 06, 2026
  

  ZAI Lab reports Q2 EPS ($0.05) vs FactSet ($0.68) [6 est, ($0.99)-(0.58)] ($18.37, 0.00)

• 07:01 AM ET Aug 03, 2026
  

  ZAI Lab confirms FDA orphan designation to Zocilurtatug Pelitecan for the treatment of neuroendocrine carcinomas (NECs) ($18.27, 0.00)

• 10:48 PM ET Aug 02, 2026
  

  StreetAccount Consensus Metrics Preview - ZAI Lab Q2 Earnings

• 06:54 AM ET Jul 30, 2026
  

  FDA grants orphan drug designation to zocilurtatug pelitecan for the treatment of neuroendocrine carcinoma ($18.31, 0.00)